Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | GRPR | P30550 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | CTSH | P09668 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766715 | 0.96 | BACE1 (0.41) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL21766780 | 0.96 | BACE1 (0.42) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL21766763 | 0.92 | BACE1 (0.40) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL23314229 | 0.92 | ERBB2 (0.40) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL21766757 | 0.92 | ERBB2 (0.40) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL21766714 | 0.92 | BACE1 (0.38) | BACE1BACE2ERBB2CTSDGRPR | |
| SCHEMBL21766788 | 0.88 | SIRT2 (0.41) | BACE1BACE2ERBB2CTSLCTSS | |
| SCHEMBL21766761 | 0.88 | BACE1 (0.41) | BACE1BACE2ERBB2GRPRCTSL | |
| SCHEMBL21766737 | 0.87 | MAGI3 (0.39) | BACE1BACE2CTSLCTSSCTSK | |
| SCHEMBL21766784 | 0.86 | ERAP2 (0.37) | BACE1BACE2ERBB2GRPRCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10994017-B2 | Nerve labeling compositions and uses thereof | AVELAS BIOSCIENCES, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | AVELAS ACQUISITION CORPORATION | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061200-A1 | NERVE LABELING COMPOSITIONS AND USES THEREOF | GAP43, NGF, PMP22 | BACE1 787/4885BACE2 728/4885ERBB2 2439/4885 |
| US-10994017-B2 | Nerve labeling compositions and uses thereof | GAP43, NGF, PMP22 | BACE1 787/4885BACE2 728/4885ERBB2 2439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.